Pre-Resection Minimally Invasive Surgical Restaging of Stage III (Mediastinal Node Positive) Non-Small Cell Lung Cancer (NSCLC)

Trial Information

Pre-Resection Minimally Invasive Surgical Restaging of Stage III (Mediastinal Node Positive) Non-Small Cell Lung Cancer (NSCLC)

OBJECTIVES:

- Evaluate the feasibility of using videothoracoscopy to access and identify residual
viable cancer in mediastinal lymph nodes and/or evaluate for other conditions that
render patients unresectable (pleural carcinomatosis or T4 primary tumors) following
prior mediastinoscopy and a period of neoadjuvant therapy in patients with stage IIIA
non-small cell lung cancer.

- Evaluate the safety (morbidity and mortality) of preresectional thoracoscopic restaging
of these patients.

- Assess the accuracy (false-negative rate) of thoracoscopic mediastinal node restaging
in these patients.

OUTLINE: Patients undergo ipsilateral videothoracoscopic evaluation for restaging their
disease after prior mediastinoscopy and induction therapy.

Patients with negative restaging procedures are strongly encouraged to undergo anatomic
resection (lobectomy, bilobectomy, or pneumonectomy) with complete mediastinal
lymphadenectomy.

Patients with a positive restaging procedure may still undergo resection at the discretion
of the surgeon and other treating physicians.

PROJECTED ACCRUAL: A total of 75 patients will be accrued for this study within 30 months.